158 related articles for article (PubMed ID: 36739265)
1. Everybody needs good neighbours: the progressive DCIS microenvironment.
Gibson SV; Roozitalab RM; Allen MD; Jones JL; Carter EP; Grose RP
Trends Cancer; 2023 Apr; 9(4):326-338. PubMed ID: 36739265
[TBL] [Abstract][Full Text] [Related]
2. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
3. Learning to distinguish progressive and non-progressive ductal carcinoma in situ.
Casasent AK; Almekinders MM; Mulder C; Bhattacharjee P; Collyar D; Thompson AM; Jonkers J; Lips EH; van Rheenen J; Hwang ES; Nik-Zainal S; Navin NE; Wesseling J;
Nat Rev Cancer; 2022 Dec; 22(12):663-678. PubMed ID: 36261705
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ: to treat or not to treat, that is the question.
van Seijen M; Lips EH; Thompson AM; Nik-Zainal S; Futreal A; Hwang ES; Verschuur E; Lane J; Jonkers J; Rea DW; Wesseling J;
Br J Cancer; 2019 Aug; 121(4):285-292. PubMed ID: 31285590
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
Campbell MJ; Baehner F; O'Meara T; Ojukwu E; Han B; Mukhtar R; Tandon V; Endicott M; Zhu Z; Wong J; Krings G; Au A; Gray JW; Esserman L
Breast Cancer Res Treat; 2017 Jan; 161(1):17-28. PubMed ID: 27785654
[TBL] [Abstract][Full Text] [Related]
6. Human Ductal Carcinoma In Situ: Advances and Future Perspectives.
Behbod F; Chen JH; Thompson A
Cold Spring Harb Perspect Med; 2023 Oct; 13(10):. PubMed ID: 36781223
[TBL] [Abstract][Full Text] [Related]
7. Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
Rosso KJ; Weiss A; Thompson AM
Surg Oncol Clin N Am; 2018 Jan; 27(1):69-80. PubMed ID: 29132566
[TBL] [Abstract][Full Text] [Related]
8. Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression.
Wilson GM; Dinh P; Pathmanathan N; Graham JD
J Mammary Gland Biol Neoplasia; 2022 Mar; 27(1):101-131. PubMed ID: 35567670
[TBL] [Abstract][Full Text] [Related]
9. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
[TBL] [Abstract][Full Text] [Related]
10. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
11. Avoiding Overtreatment of Ductal Carcinoma in situ.
van der Borden CL; Stoffers S; Lips EH; Wesseling J
Trends Cancer; 2019 Jul; 5(7):391-393. PubMed ID: 31311652
[TBL] [Abstract][Full Text] [Related]
12. Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.
Carraro DM; Elias EV; Andrade VP
Biosci Rep; 2014 Feb; 34(1):. PubMed ID: 27919043
[TBL] [Abstract][Full Text] [Related]
13. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
Sakorafas GH; Tsiotou AG
Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
[TBL] [Abstract][Full Text] [Related]
14. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
15. An Organotypic Mammary Duct Model Capturing Matrix Mechanics-Dependent Ductal Carcinoma
Kulwatno J; Gong X; DeVaux R; Herschkowitz JI; Mills KL
Tissue Eng Part A; 2021 Apr; 27(7-8):454-466. PubMed ID: 33397202
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
17. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling.
DeVaux RS; Ropri AS; Grimm SL; Hall PA; Herrera EO; Chittur SV; Smith WP; Coarfa C; Behbod F; Herschkowitz JI
J Cell Biochem; 2020 Jul; 121(7):3465-3478. PubMed ID: 31907974
[TBL] [Abstract][Full Text] [Related]
20. Ductal carcinoma in situ: treatment or active surveillance?
Kuerer HM
Expert Rev Anticancer Ther; 2015; 15(7):777-85. PubMed ID: 25938920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
